[{"address1": "480 Arsenal Way", "address2": "Suite 100", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 207 8979", "website": "https://acrivon.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter  Blume-Jensen M.D., Ph.D.", "age": 62, "title": "Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 1068552, "exercisedValue": 0, "unexercisedValue": 954258}, {"maxAge": 1, "name": "Ms. Kristina  Masson M.B.A., Ph.D.", "age": 45, "title": "Co-Founder, Executive VP of Business Operations, Site Head, Treasurer & Director", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 824474, "exercisedValue": 0, "unexercisedValue": 513086}, {"maxAge": 1, "name": "Dr. Eric J. Devroe Ph.D.", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 774026, "exercisedValue": 0, "unexercisedValue": 583150}, {"maxAge": 1, "name": "Dr. Adam D. Levy M.B.A., Ph.D.", "age": 59, "title": "CFO & Principal Financial Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Katharine  Peterson CPA", "title": "Vice President of Finance & Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bruce  Close", "title": "Vice President of Quality & Compliance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary-Alice  Miller J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 587108, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Erick  Gamelin M.D., Ph.D.", "age": 67, "title": "Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 480723, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jesper V. Olsen Ph.D.", "title": "Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joon  Jung Ph.D.", "title": "VP & Head of Data Science", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.03, "open": 2.04, "dayLow": 1.96, "dayHigh": 2.1, "regularMarketPreviousClose": 2.03, "regularMarketOpen": 2.04, "regularMarketDayLow": 1.96, "regularMarketDayHigh": 2.1, "payoutRatio": 0.0, "beta": 1.753, "forwardPE": -1.1006712, "volume": 836843, "regularMarketVolume": 836843, "averageVolume": 1758580, "averageVolume10days": 6150670, "averageDailyVolume10Day": 6150670, "bid": 2.03, "ask": 2.1, "bidSize": 20, "askSize": 20, "marketCap": 64688008, "fiftyTwoWeekLow": 1.05, "fiftyTwoWeekHigh": 8.0, "allTimeHigh": 25.47, "allTimeLow": 1.05, "fiftyDayAverage": 2.283, "twoHundredDayAverage": 1.68535, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -61576992, "profitMargins": 0.0, "floatShares": 16789220, "sharesOutstanding": 31555126, "sharesShort": 5325324, "sharesShortPriorMonth": 4356053, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.1688, "heldPercentInsiders": 0.20567, "heldPercentInstitutions": 0.56054, "shortRatio": 11.85, "shortPercentOfFloat": 0.4458, "impliedSharesOutstanding": 31555126, "bookValue": 4.076, "priceToBook": 0.50294405, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -81751000, "trailingEps": -2.12, "forwardEps": -1.8625, "enterpriseToEbitda": 0.703, "52WeekChange": -0.6348921, "SandP52WeekChange": 0.14987159, "quoteType": "EQUITY", "currentPrice": 2.05, "targetHighPrice": 19.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.5, "targetMedianPrice": 10.5, "recommendationMean": 1.55556, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 129254000, "totalCashPerShare": 4.096, "ebitda": -87654000, "totalDebt": 2989000, "quickRatio": 8.68, "currentRatio": 8.754, "debtToEquity": 2.324, "returnOnAssets": -0.30888, "returnOnEquity": -0.50232, "freeCashflow": -40886000, "operatingCashflow": -65788000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ACRV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Acrivon Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1769216325, "regularMarketTime": 1769202002, "exchange": "NGM", "messageBoardId": "finmb_652690313", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.985221, "regularMarketPrice": 2.05, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1668522600000, "postMarketChangePercent": -1.4634132, "postMarketPrice": 2.02, "postMarketChange": -0.029999971, "regularMarketChange": 0.02, "regularMarketDayRange": "1.96 - 2.1", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1758580, "fiftyTwoWeekLowChange": 1.0, "fiftyTwoWeekLowChangePercent": 0.952381, "fiftyTwoWeekRange": "1.05 - 8.0", "fiftyTwoWeekHighChange": -5.95, "fiftyTwoWeekHighChangePercent": -0.74375, "fiftyTwoWeekChangePercent": -63.489212, "earningsTimestampStart": 1755201600, "earningsTimestampEnd": 1755201600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.12, "epsForward": -1.8625, "epsCurrentYear": -1.96375, "longName": "Acrivon Therapeutics, Inc.", "priceEpsCurrentYear": -1.043921, "fiftyDayAverageChange": -0.23300004, "fiftyDayAverageChangePercent": -0.102058716, "twoHundredDayAverageChange": 0.36465, "twoHundredDayAverageChangePercent": 0.21636456, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-15", "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "displayName": "Acrivon Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-24"}]